Clinical Trial

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2023 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-07-06.
Status change: Not Yet Recruiting → Recruiting 2023-05-19
Trial Details
NCT Number NCT05447702
Lead Sponsor West China Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Triple Negative Breast Cancer
Enrollment 35 participants
Start Date 2022-11-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-22